More recently, Bluebird Bio’s Zynteglo (betibeglogene autotemcel), a cell-based gene therapy ... adeno-associated virus/AAV, capsids, herpes simplex virus/HSV, and virus-like particles/VLPs ...

The AAV segment is ... new targets for particular gene therapy and improve molecular structures, giving researchers important information for the purpose of drug development. Overall, artificial ...

Gene therapy involves the introduction of new genes ... α1,3-galactosyltransferase was evaluated in monkeys with CRISPR-induced primary hepatocellular carcinoma and in a phase I clinical trial.

Retinal gene therapy advancements may rewrite the book on treatments for age-related macular degeneration and diabetic eye diseases.

According to latest report, the U.S. cell and gene therapy CDMO market size was valued at USD 3.19 billion in 2024 and is projected to hit around USD 33.24 billion by 2034, growing at a compound ...

The expansion of the advanced therapy medicinal products market is primarily fueled by the increasing incidence of chronic diseases. The rising prevalence of genetic disorders and cancer, along ...

The treatment, called MCO-010 (sonpiretigene isteparvovec), comprises a gene that codes for the ambient light-sensitive MCO protein carried by an adeno-associated virus (AAV) vector, which is ...

LETI-101 has demonstrated therapeutically relevant reductions of mutant huntingtin (HTT) protein, exceeding 80%, while preserving essential wild-type ...